GLP-1 Agonists for Obesity-Reply.
作者信息
Mozaffarian Dariush
机构信息
Food Is Medicine Institute, Tufts University, Boston, Massachusetts.
出版信息
JAMA. 2024 Aug 27;332(8):675-676. doi: 10.1001/jama.2024.12077.
PMID:39083314
Abstract
摘要
相似文献
1
GLP-1 Agonists for Obesity-Reply.用于肥胖症的胰高血糖素样肽-1激动剂——回应
JAMA. 2024 Aug 27;332(8):675-676. doi: 10.1001/jama.2024.12077.
2
GLP-1 Agonists for Obesity.用于治疗肥胖症的胰高血糖素样肽-1激动剂
JAMA. 2024 Aug 27;332(8):673. doi: 10.1001/jama.2024.12074.
3
GLP-1 Agonists for Obesity.用于治疗肥胖症的胰高血糖素样肽-1激动剂
JAMA. 2024 Aug 27;332(8):674-675. doi: 10.1001/jama.2024.12065.
4
GLP-1 Agonists for Obesity.用于治疗肥胖症的胰高血糖素样肽-1激动剂
JAMA. 2024 Aug 27;332(8):672-673. doi: 10.1001/jama.2024.12071.
5
Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.胰高血糖素样肽-1（GLP-1）和GLP-1-葡萄糖依赖性促胰岛素多肽（GIP）双受体激动剂的公平分配
N Engl J Med. 2024 May 30;390(20):1839-1842. doi: 10.1056/NEJMp2400978. Epub 2024 Apr 17.
6
Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity-Reply.替尔泊肽用于肥胖成人减重维持——回复
JAMA. 2024 May 21;331(19):1676. doi: 10.1001/jama.2024.2603.
7
Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.司美格鲁肽、肥胖相关心力衰竭与2型糖尿病。回复。
N Engl J Med. 2024 Jul 25;391(4):381-382. doi: 10.1056/NEJMc2406233.
8
Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023.2020 - 2023年向青少年和青年成年人发放胰高血糖素样肽-1受体激动剂的情况
JAMA. 2024 Jun 18;331(23):2041-2043. doi: 10.1001/jama.2024.7112.
9
Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.减重手术后胰高血糖素样肽-1 受体激动剂与其他减肥药的不良事件比较。
Diabetes Obes Metab. 2024 Sep;26(9):3906-3913. doi: 10.1111/dom.15737. Epub 2024 Jun 27.
10
Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.司美格鲁肽、肥胖相关心力衰竭与2型糖尿病
N Engl J Med. 2024 Jul 25;391(4):381. doi: 10.1056/NEJMc2406233.
引用本文的文献
1
Opportunities for General Internal Medicine to Promote Equity in Obesity Care.普通内科促进肥胖症护理公平性的机遇。
J Gen Intern Med. 2024 Oct 16. doi: 10.1007/s11606-024-09084-z.
Zotero 插件